Beard et al., 2015 - Google Patents
Continual low-dose infusion of sulfamidase is superior to intermittent high-dose delivery in ameliorating neuropathology in the MPS IIIA mouse brainBeard et al., 2015
View HTML- Document ID
- 4345145194590963679
- Author
- Beard H
- Hassiotis S
- Luck A
- Rozaklis T
- Hopwood J
- Hemsley K
- Publication year
- Publication venue
- JIMD Reports, Volume 29
External Links
Snippet
Abstract Mucopolysaccharidosis IIIA (MPS IIIA) is a neurodegenerative lysosomal storage disorder characterised by progressive loss of learned skills, sleep disturbance and behavioural problems. Reduced activity of lysosomal sulfamidase results in accumulation of …
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Heinz et al. | Reduced central serotonin transporters in alcoholism | |
Muenzer et al. | A phase I/II study of intrathecal idursulfase-IT in children with severe mucopolysaccharidosis II | |
Vogler et al. | Enzyme replacement in murine mucopolysaccharidosis type VII: neuronal and glial response to β-glucuronidase requires early initiation of enzyme replacement therapy | |
Rafi et al. | Extended normal life after AAVrh10-mediated gene therapy in the mouse model of Krabbe disease | |
Chen et al. | Comparing routes of delivery for nanoliposomal irinotecan shows superior anti-tumor activity of local administration in treating intracranial glioblastoma xenografts | |
Vite et al. | Effective gene therapy for an inherited CNS disease in a large animal model | |
Gill et al. | Direct brain infusion of glial cell line–derived neurotrophic factor in Parkinson disease | |
Savas et al. | Intracerebral injection of sulfamidase delays neuropathology in murine MPS-IIIA | |
US10080783B2 (en) | Intraventricular enzyme delivery for lysosomal storage diseases | |
US7442372B2 (en) | Delivery of therapeutic compounds to the brain and other tissues | |
Calias et al. | CNS penetration of intrathecal-lumbar idursulfase in the monkey, dog and mouse: implications for neurological outcomes of lysosomal storage disorder | |
Hemsley et al. | Effect of high dose, repeated intra‐cerebrospinal fluid injection of sulphamidase on neuropathology in mucopolysaccharidosis type IIIA mice | |
Beard et al. | Determination of the role of injection site on the efficacy of intra-CSF enzyme replacement therapy in MPS IIIA mice | |
Nagahara et al. | MR-guided delivery of AAV2-BDNF into the entorhinal cortex of non-human primates | |
Xu et al. | Large-volume intrathecal enzyme delivery increases survival of a mouse model of late infantile neuronal ceroid lipofuscinosis | |
Hemsley et al. | Examination of intravenous and intra‐CSF protein delivery for treatment of neurological disease | |
Vegting et al. | The effects of ecstasy on neurotransmitter systems: a review on the findings of molecular imaging studies | |
King et al. | Low‐dose, continuous enzyme replacement therapy ameliorates brain pathology in the neurodegenerative lysosomal disorder mucopolysaccharidosis type IIIA | |
Marcó et al. | Seven-year follow-up of durability and safety of AAV CNS gene therapy for a lysosomal storage disorder in a large animal | |
Sohn et al. | Improvement of CNS defects via continuous intrathecal enzyme replacement by osmotic pump in mucopolysaccharidosis type II mice | |
Xhima et al. | Ultrasound delivery of a TrkA agonist confers neuroprotection to Alzheimer-associated pathologies | |
Huttunen et al. | Intraputamenal cerebral dopamine neurotrophic factor in Parkinson's disease: a randomized, double‐blind, multicenter phase 1 trial | |
Banks et al. | Effects of cocaine and MDMA self-administration on serotonin transporter availability in monkeys | |
Pienaar et al. | The cellular diversity of the pedunculopontine nucleus: relevance to behavior in health and aspects of Parkinson’s disease | |
King et al. | Evaluation of enzyme dose and dose-frequency in ameliorating substrate accumulation in MPS IIIA Huntaway dog brain |